CORT · Corcept Therapeutics Inc
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Jul 29, 2026TL;DR. Corcept reported Q2 revenue of $256.1 million (up 32% year-over-year) driven by a strong first quarter of Lifyorli availability ($47.6 million) and continued Korlym growth, and raised full-year 2026 revenue guidance to $1.1–$1.2 billion, with key clinical readouts (MONARCH MASH, DAZALS ALS, BELLA ovarian) expected by year-end.
- + Q2 revenue rose 32% year-over-year to $256.1 million, with $208.6 million from Korlym and $47.6 million from the first quarter of Lifyorli.
- + Raised 2026 full-year revenue guidance to $1.1–$1.2 billion.
- + Cushing's syndrome business posted a record number of new prescriptions, first-time prescribers, and patients on therapy.
- + Cash and investments increased to $544.6 million at June 30, 2026, from $515.4 million at March 31, 2026.
- − Operating expenses jumped to $214.8 million in Q2 2026 from $167.8 million in Q2 2025, driven by Lifyorli launch costs and Cushing's investments.
- − Relacorilant Cushing's syndrome NDA previously received a Complete Response Letter; approval is now pending the December 17, 2026 PDUFA.
- − Dazucorilant ALS program saw discontinuations driven by non-serious GI distress, requiring a dose-titration study before the planned Phase 3.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CORT
this stock
Corcept Therapeutics Inc
|
$12.60B | +229.7% | +12.8% | 277.6 | 8.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +16.2% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -2.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CORT | -2.4% | +1.2% | +174.0% | +1.2% | +229.7% |
| SPY | -1.2% | -0.4% | +13.1% | -0.4% | +12.1% |
| vs SPY | -1.2% | +1.6% | +161.0% | +1.6% | +217.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.